FORM 4

Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject	
to Section 16. Form 4 or Form 5	
obligations may continue. See	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  LILLY ENDOWMENT INC						2. Issuer Name <b>and</b> Ticker or Trading Symbol ELI LILLY & Co [ LLY ]									Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director X 10% Owner						
						0 Saturd Feeting Transaction (1) 11 (5) (1)									Director Officer (give title			Other (			
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 06/10/2021									below) below)							
2801 NORTH MERIDIAN STREET						4 If Amandment Data of Original Filed (Manth/Dau)(Co.)									6. Individual or Joint/Group Filing (Check Applicable						
(Street)						If Amendment, Date of Original Filed (Month/Day/Year)									Line)						
INDIANAPOLIS IN 46208-0068														X Form filed by One Reporting Person Form filed by More than One Reporting							
(City)										Person											
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
Date				2. Transaction Date (Month/Day/Ye	Executio		n Date,	3. Transaction Code (Instr. 8)		ı   Di	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and				Beneficially Owned Foll		Forn (D) o Indir	n: Direct or ect (I)	7. Nature of Indirect Beneficial Ownership		
							Code	v	Ai	mount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)		(Inst	r. 4)	(Instr. 4)			
Common Stock				06/10/2021				S			19,321	D	\$232.	353(1)	109,	9,632,779		D			
Common Stock				06/10/2021				S		1	120,475	D	\$233.	174 <sup>(2)</sup>	109,	109,512,304		D			
Common	Stock		06/10/202	1			S			57,008	D	\$233.	.888 <sup>(3)</sup> 109,4		455,296		D				
Common	Stock		06/10/2021				S			42,596	D	\$235.152(4)		109,412,700		D					
Common	Stock		06/10/2021				S			600	D	\$235.	668 <sup>(5)</sup>	109,412,100		100 D					
		Tal	ole	II - Derivati (e.g., pu							osed of, converti				Owned	t					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exe if ar	Deemed cution Date, ny nth/Day/Year)		action (Instr.	5. Numl of Derivati Securiti Acquire (A) or Dispose of (D) (Instr. 3 and 5)	Expiration (Month/Daties ed					7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	V (A) (D) Date Exercisab				able	Expiratior Date	ı Title	Amour or Number of Shares	er							

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$231.635 to \$232.63, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4) and (5) to this Form 4.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$232.635 to \$233.63, inclusive.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$233.635 to \$234.63, inclusive.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$234.65 to \$235.645, inclusive.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold at prices of \$235.665 and \$235.68, inclusive.

## Remarks:

/s/Diane M. Stenson, Vice behalf of Lilly Endowment

06/11/2021

Inc.

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.